title: Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer.
abstract: OBJECTIVE
  To further evaluate the association between the cytoplasmic or nuclear localization of ErbB3 with biochemical recurrence (BCR) in patients with prostate cancer and positive surgical margins, as there is a greater risk of BCR for such patients after radical prostatectomy (RP).
  
  
  METHODS
  We recently noted that ErbB3, which is normally associated with the plasma membrane, can translocate to the nucleus, an event which appears to be associated with disease progression. We evaluated ErbB3 expression and localization using immunohistochemistry on tissue samples from 55 patients with positive surgical margins after RP; 30 of these 55 (55%) had BCR after 3 years of follow-up. The relationship between ErbB3 nuclear localization and BCR (prostate-specific antigen, PSA, >0.3 ng/mL) after RP was analysed by Kaplan-Meier survival analysis and Cox regression models.
  
  
  RESULTS
  The BCR-free survival probability at 3 years was 0.65 and 0.35 for positive and negative nuclear ErbB3, respectively (Kaplan-Meier, P = 0.029). Patients negative for nuclear ErbB3 had a 2.47-fold increase in BCR frequency in a univariate Cox model (P = 0.008) and it remained an independent prognostic marker when combined with clinical prognostic variables in a multivariate model (P = 0.023).
  
  
  CONCLUSIONS
  Low nuclear localization of ErbB3 is a predictor of BCR in patients with prostate cancer and positive surgical margins after RP.
authors.affiliation: Centre de recherche du Centre Hospitalier de l'Université de Montréal and Institut du cancer de Montréal, Montreal, Quebec, Canada.
authors.forename: Ismaël H
authors.initials: IH
authors.lastname: Koumakpayi
authors.forename: Jean-Simon
authors.initials: JS
authors.lastname: Diallo
authors.forename: Cécile
authors.initials: C
authors.lastname: Le Page
authors.forename: Laurent
authors.initials: L
authors.lastname: Lessard
authors.forename: Abdelali
authors.initials: A
authors.lastname: Filali-Mouhim
authors.forename: Louis R
authors.initials: LR
authors.lastname: Bégin
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Mes-Masson
authors.forename: Fred
authors.initials: F
authors.lastname: Saad
mesh_terms: D000368:Aged; D015153:Blotting, Western; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality; D020893:Receptor, ErbB-3 / Q000378:metabolism*; D012044:Regression Analysis; D016019:Survival Analysis
chemical_list: D020893:Receptor, ErbB-3; D017430:Prostate-Specific Antigen